FAPI PET/CT Imaging—An Updated Review

Kunal Ramesh Chandekar; Arun Prashanth; Sobhan Vinjamuri; Rakesh Kumar

doi:10.3390/diagnostics13122018

journal article Open Access Jun 09, 2023

FAPI PET/CT Imaging—An Updated Review

Kunal Ramesh Chandekar Arun Prashanth Sobhan Vinjamuri Rakesh Kumar

Diagnostics Vol. 13 No. 12 pp. 2018 · MDPI AG

View at Publisher Save 10.3390/diagnostics13122018

Abstract

Despite revolutionizing the field of oncological imaging, Positron Emission Tomography (PET) with [18F]Fluorodeoxyglucose (FDG) as its workhorse is limited by a lack of specificity and low sensitivity in certain tumor subtypes. Fibroblast activation protein (FAP), a type II transmembrane glycoprotein, is expressed by cancer-associated fibroblasts (CAFs) that form a major component of the tumor stroma. FAP holds the promise to be a pan-cancer target, owing to its selective over-expression in a vast majority of neoplasms, particularly epithelial cancers. Several radiolabeled FAP inhibitors (FAPI) have been developed for molecular imaging and potential theranostic applications. Preliminary data on FAPI PET/CT remains encouraging, with extensive multi-disciplinary clinical research currently underway. This review summarizes the existing literature on FAPI PET/CT imaging with an emphasis on diagnostic applications, comparison with FDG, pitfalls, and future directions.

Topics

No keywords indexed for this article. Browse by subject →

References

160

[1]

Molecular imaging in oncology: Current impact and future directions

Steven P. Rowe, Martin G. Pomper

CA: A Cancer Journal for Clinicians 2022 10.3322/caac.21713

[2]

A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications

Michelle L. James, Sanjiv S. Gambhir

Physiological Reviews 2012 10.1152/physrev.00049.2010

[3]

Alavi "Guest Editorial: The Conception of FDG-PET Imaging" Semin. Nucl. Med. (2002) 10.1053/snuc.2002.29269

[4]

Basu "Unparalleled Contribution of 18F-FDG PET to Medicine over 3 Decades" J. Nucl. Med. (2008)

[5]

Nunes "Theranostics in Nuclear Medicine: Emerging and Re-Emerging Integrated Imaging and Therapies in the Era of Precision Oncology" RadioGraphics (2020) 10.1148/rg.2020200021

[6]

Old "Cell Surface Glycoprotein of Reactive Stromal Fibroblasts as a Potential Antibody Target in Human Epithelial Cancers" Proc. Natl. Acad. Sci. USA (1990) 10.1073/pnas.87.18.7235

[7]

Calais "FAP: The Next Billion Dollar Nuclear Theranostics Target?" J. Nucl. Med. (2020) 10.2967/jnumed.119.241232

[8]

Flier "Tumors: Wounds That Do Not Heal. Similarities between Tumor Stroma Generation and Wound Healing" N. Engl. J. Med. (1986) 10.1056/nejm198612253152606

[9]

Whiteside "The Tumor Microenvironment and Its Role in Promoting Tumor Growth" Oncogene (2008) 10.1038/onc.2008.271

[10]

A framework for advancing our understanding of cancer-associated fibroblasts

Erik Sahai, Igor Astsaturov, Edna Cukierman et al.

Nature Reviews Cancer 2020 10.1038/s41568-019-0238-1

[11]

Park "Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts" J. Biol. Chem. (1999) 10.1074/jbc.274.51.36505

[12]

Scanlan "Molecular Cloning of Fibroblast Activation Protein Alpha, a Member of the Serine Protease Family Selectively Expressed in Stromal Fibroblasts of Epithelial Cancers" Proc. Natl. Acad. Sci. USA (1994) 10.1073/pnas.91.12.5657

[13]

Dohi "Histogenesis-Specific Expression of Fibroblast Activation Protein and Dipeptidylpeptidase-IV in Human Bone and Soft Tissue Tumours" Histopathology (2009) 10.1111/j.1365-2559.2009.03399.x

[14]

Cohen "Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma" Pancreas (2008) 10.1097/mpa.0b013e31816618ce

[15]

High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes

Mairene Coto-Llerena, Caner Ercan, Venkatesh Kancherla et al.

Frontiers in Oncology 2020 10.3389/fonc.2020.00979

[16]

Targeting of activated fibroblasts for imaging and therapy

Thomas Lindner, Anastasia Loktev, Frederik Giesel et al.

EJNMMI Radiopharmacy and Chemistry 2019 10.1186/s41181-019-0069-0

[17]

Xin "Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review" Front. Oncol. (2021) 10.3389/fonc.2021.648187

[18]

Welt "Antibody Targeting in Metastatic Colon Cancer: A Phase I Study of Monoclonal Antibody F19 against a Cell-Surface Protein of Reactive Tumor Stromal Fibroblasts" J. Clin. Oncol. (1994) 10.1200/jco.1994.12.6.1193

[19]

Scott "A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-Positive Cancer" Clin. Cancer Res. (2003)

[20]

Garousi "Imaging Using Radiolabelled Targeted Proteins: Radioimmunodetection and Beyond" EJNMMI Radiopharm. Chem. (2020) 10.1186/s41181-020-00094-w

[21]

Adams "PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, Has Potent Antitumor Effects and Augments Antibody-Mediated Cytotoxicity via a Novel Immune Mechanism" Cancer Res. (2004) 10.1158/0008-5472.can-04-0447

[22]

Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold

Koen Jansen, Leen Heirbaut, Jonathan D. Cheng et al.

ACS Medicinal Chemistry Letters 2013 10.1021/ml300410d

[23]

Jansen "Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)Glycyl-2-Cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)" J. Med. Chem. (2014) 10.1021/jm500031w

[24]

A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts

Anastasia Loktev, Thomas Lindner, Walter Mier et al.

Journal of Nuclear Medicine 2018 10.2967/jnumed.118.210435

[25]

Lindner "Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein" J. Nucl. Med. (2018) 10.2967/jnumed.118.210443

[26]

Loktev "Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention" J. Nucl. Med. (2019) 10.2967/jnumed.118.224469

[27]

Moon "Targeting Fibroblast Activation Protein (FAP): Next Generation PET Radiotracers Using Squaramide Coupled Bifunctional DOTA and DATA5m Chelators" EJNMMI Radiopharm. Chem. (2020) 10.1186/s41181-020-00102-z

[28]

Moon "Fibroblast Activation Protein (FAP) Targeting Homodimeric FAP Inhibitor Radiotheranostics: A Step to Improve Tumor Uptake and Retention Time" Am. J. Nucl. Med. Mol. Imaging (2021)

[29]

Ballal "Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study" Thyroid. (2021)

[30]

Xu "Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy" J. Nucl. Med. (2022) 10.2967/jnumed.121.262533

[31]

Kelly "A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα)" Mol. Imaging Biol. (2021) 10.1007/s11307-021-01593-1

[32]

Millul "An Ultra-High-Affinity Small Organic Ligand of Fibroblast Activation Protein for Tumor-Targeting Applications" Proc. Natl. Acad. Sci. USA (2021) 10.1073/pnas.2101852118

[33]

Toms "Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor" J. Nucl. Med. (2020) 10.2967/jnumed.120.242958

[34]

Giesel "FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients" J. Nucl. Med. (2021) 10.2967/jnumed.120.245084

[35]

Lindner "Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy" J. Nucl. Med. (2020) 10.2967/jnumed.119.239731

[36]

Roy "Design and Validation of Fibroblast Activation Protein Alpha Targeted Imaging and Therapeutic Agents" Theranostics (2020) 10.7150/thno.41409

[37]

Slania "Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-Glycyl-2-Cyanopyrrolidine-Based Small Molecules" J. Med. Chem. (2021) 10.1021/acs.jmedchem.0c02171

[38]

Ferdinandus "Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients" J. Nucl. Med. (2022)

[39]

Watabe "Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models" J. Nucl. Med. (2020) 10.2967/jnumed.119.233122

[40]

Zboralski "Preclinical Evaluation of FAP-2286 for Fibroblast Activation Protein Targeted Radionuclide Imaging and Therapy" Eur. J. Nucl. Med. Mol. Imaging (2022) 10.1007/s00259-022-05842-5

[41]

Baum "Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177 Lu-FAP-2286: First-in-Humans Results" J. Nucl. Med. (2022) 10.2967/jnumed.120.259192

[42]

Rao "[177Lu]Lu-FAP-2286 Therapy in a Case of Right Lung Squamous Cell Carcinoma with Systemic Metastases" Eur. J. Nucl. Med. Mol. Imaging (2023) 10.1007/s00259-022-06048-5

[43]

Fitzgerald "The Role of Fibroblast Activation Protein in Health and Malignancy" Cancer Metastasis Rev. (2020) 10.1007/s10555-020-09909-3

[44]

Ballal "Biodistribution, Pharmacokinetics, Dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the Head-to-Head Comparison with [18F]F-FDG PET/CT in Patients with Various Cancers" Eur. J. Nucl. Med. Mol. Imaging (2021) 10.1007/s00259-020-05132-y

[45]

Giesel "68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers" J. Nucl. Med. (2019) 10.2967/jnumed.118.215913

[46]

Meyer "Radiation Dosimetry and Biodistribution of 68 Ga-FAPI-46 PET Imaging in Cancer Patients" J. Nucl. Med. (2020) 10.2967/jnumed.119.236786

[47]

Wang "Dynamic PET/CT Imaging of 68Ga-FAPI-04 in Chinese Subjects" Front. Oncol. (2021) 10.3389/fonc.2021.651005

[48]

Hetzheim "Radiation Dosimetry of 68Ga-PSMA-11 (HBED-CC) and Preliminary Evaluation of Optimal Imaging Timing" Eur. J. Nucl. Med. Mol. Imaging (2016) 10.1007/s00259-016-3419-0

[49]

Velikyan "Comparative Biodistribution and Radiation Dosimetry of 68 Ga-DOTATOC and 68 Ga-DOTATATE in Patients with Neuroendocrine Tumors" J. Nucl. Med. (2013) 10.2967/jnumed.113.120600

[50]

Johansson "Effective Dose from Radiopharmaceuticals" Eur. J. Nucl. Med. (1992) 10.1007/bf00175858

Showing 50 of 160 references

Cited By

101

Fibroblast Activation Protein-Targeted Radioligand Therapy (FAP RLT) in Gastroenteropancreatic Malignancies: Biological Rationale, Clinical Evidence, and Future Directions

Deya' Aldeen Sweedat, Saad Ruzzeh · 2026

World Journal of Nuclear Medicine

Metrics

101

Citations

160

References

Details

Published: Jun 09, 2023
Vol/Issue: 13(12)
Pages: 2018
License: View

Authors

K

Kunal Ramesh Chandekar

Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi 110029, India

A

Arun Prashanth

Department of Nuclear Medicine, MIOT International Hospital, Chennai 600089, India

S

Sobhan Vinjamuri

Department of Nuclear Medicine, Royal Liverpool and Broadgreen University Hospital, Liverpool L7-8YE, UK

R

Rakesh Kumar

Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi 110029, India

Cite This Article

Kunal Ramesh Chandekar, Arun Prashanth, Sobhan Vinjamuri, et al. (2023). FAPI PET/CT Imaging—An Updated Review. Diagnostics, 13(12), 2018. https://doi.org/10.3390/diagnostics13122018

FAPI PET/CT Imaging—An Updated Review

You May Also Like